Premium
A double‐blind randomized controlled trial of mifepristone or placebo before buccal misoprostol for abortion at 14–21 weeks of pregnancy
Author(s) -
Dabash Rasha,
Chelli Héla,
Hajri Selma,
Shochet Tara,
Raghavan Sheila,
Winikoff Beverly
Publication year - 2015
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2015.02.023
Subject(s) - medicine , misoprostol , mifepristone , obstetrics , abortion , placebo , randomized controlled trial , pregnancy , gynecology , randomization , surgery , genetics , alternative medicine , pathology , biology
Objective To assess differences in outcomes of misoprostol with or without mifepristone for second‐trimester abortion. Methods A randomized, double‐blind, placebo‐controlled trial of buccal misoprostol following placebo or 200 mg mifepristone was done in Tunisia among women presenting for abortions at 14–21 weeks of pregnancy between August 2009 and December 2011. Women with a live fetus, a closed cervical os, no cervical bleeding, and no contraindications to study drugs were eligible and underwent randomization (block size 10). Participants returned 24 hours later to receive 400 μg buccal misoprostol every 3 hours until complete fetal and placental expulsion (maximum 10 doses, five per 24‐hour period). The primary outcomes were rates of complete uterine evacuation at 48 hours and time to expulsion. Results A total of 120 women were evenly randomized to treatment. Complete uterine evacuation at 48 hours was recorded in 55 (91.7%) women in the combined group versus 43 (71.7%) in the misoprostol alone group (relative risk 1.28; 95% confidence interval 1.07–1.53). Mean time to complete abortion was 10.4 ± 6.6 hours in the group who received mifepristone versus 20.6 ± 9.7 hours in the misoprostol alone group ( P < 0.001). Side effects were similar in both groups. Conclusion Adding mifepristone before misoprostol can improve the quality of second‐trimester abortion care by making the process faster. ClinicalTrials.gov : NCT00969982.